α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and the formation of aggregates (Lewy bodies) in neurons. alpha-Synuclein is the major protein in Lewy bodies and rare mutations in alpha-synuclein cause early-onset PD. Consequently, alpha-synuclein is implicated in the pathogenesis of PD. Here, we have investigated the degradation pathways of alpha-synuclein, using a stable inducible PC12 cell model, where the expression of exogenous human wild-type, A30P, or A53T alpha-synuclein can be switched on and off. We have used a panel of inhibitors/stimulators of autophagy and proteasome function and followed alpha-synuclein degradation in these cells. We found that not only is alpha-synuclein degraded by the proteasome, but it is also degraded by autophagy. A role for autophagy was further supported by the presence of alpha-synuclein in organelles with the ultrastructural features of autophagic vesicles. Since rapamycin, a stimulator of autophagy, increased clearance of alpha-synuclein, it merits consideration as a potential therapeutic for Parkinsons disease, as it is designed for chronic use in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, mutant forms of synuclein and oligomers are dependent on the autophagy–lysosome pathway for their clearance4–6.”
From Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice (2018) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies suggest that α-synuclein is degraded by macroautophagy, chaperone-mediated autophagy, and the proteasome20–23.”
From Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration (2020) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Macroautophagy is a key pathway for the clearance of aggregate-prone cytosolic proteins.”
From Lithium induces autophagy by inhibiting inositol monophosphatase (2005) · cites this paper as Webb et al., 2003
In the citing paper
“Early evidence suggested roles for CMA and macroautophagy in degrading SNCA/α‐synuclein (Webb et al, 2003; Cuervo et al, 2004).”
From Autophagy in major human diseases (2021) · cites this paper as Webb et al, 2003
In the citing paper
“We previously showed that EGFP-HDQ74 is cleared by autophagy.”
From Lithium induces autophagy by inhibiting inositol monophosphatase (2005) · cites this paper as Webb et al., 2003
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Greene, L. A., & Tischler, A. S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.7.2424 · Cited by 5,553
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
A Drosophila model of Parkinson's disease
Feany, M. B., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,118
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571
Conway, K. A., Harper, J. D., & Lansbury, P. T. (1998) · Nature Medicine · doi:10.1038/3311 · Cited by 1,499
Research works printed but not linked: 2
- Furlong, R. A., Narain, Y., Rankin, J., Wyttenbach, A., and Rubinsztein, D. C. (2000) Biochem. J. 346, 577-581 · DOI · Paper page
- Biederbick, A., Kern, H. F., and Elsasser, H. P. (1995) Eur. J. Cell Biol. 66, 3-14
Cited by
Items 101–200 of 1,001
Sarkar, S. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130134 · Cited by 370
Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., Hansen, L., Adame, A., Galasko, D., & Masliah, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009313 · Cited by 367
RetractedWang, I.-F., Guo, B.-S., Liu, Y.-C., Wu, C.-C., Yang, C.-H., Tsai, K.-J., & Shen, C.-K. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206362109 · Cited by 377
“In parallel, it has been found that rapamycin, through the enhancement of autophagy, could help the clearance of aggregation-prone proteins, including the mutant huntingtin protein (21), α-synuclein (24, 32), β-amyloid (23), and the pathological prion protein (33).”
BackgroundGlucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Parkinsonism among Gaucher disease carriers
Goker-Alpan, O., Schiffmann, R., LaMarca, M. E., Nussbaum, R. L., McInerney-Leo, A., & Sidransky, E. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024455 · Cited by 366
di Domenico, A., Carola, G., Calatayud, C., Pons-Espinal, M., Muñoz, J. P., Richaud-Patin, Y., Fernandez-Carasa, I., Gut, M., Faella, A., Parameswaran, J., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.12.011 · Cited by 372
“…these cells. a-syn has previously been shown to undergo degradation both by the ubiquitin/proteasome system and by autophagy (Cuervo et al., 2004; Webb et al., 2003); therefore a-syn flux in the presence of lysosomal and proteasome inhibitors (leupeptin and lactacystin, respectively) was…”
BackgroundCellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation
Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 363
“Studies on α-synuclein degradation have shown that it can be degraded through the proteasome pathway, but more importantly by autophagy (Webb et al. 2003).”
BackgroundXilouri, M., Vogiatzi, T., Vekrellis, K., Park, D., & Stefanis, L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005515 · Cited by 354
The mTOR signalling cascade: paving new roads to cure neurological disease
Crino, P. B. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.81 · Cited by 368
Role of O-linked N-acetylglucosamine protein modification in cellular (patho)physiology
Chatham, J. C., Zhang, J., & Wende, A. R. (2021) · Physiological Reviews · doi:10.1152/physrev.00043.2019 · Cited by 352
Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling
Gorman, A. M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00402.x · Cited by 362
Neurodegenerative lysosomal disorders: A continuum from development to late age
Nixon, R. A., Yang, D.-S., & Lee, J.-H. (2008) · Autophagy · doi:10.4161/auto.6259 · Cited by 362
Neuronal autophagy and neurodegenerative diseases
Son, J. H., Shim, J. H., Kim, K.-H., Ha, J.-Y., & Han, J. Y. (2012) · Experimental & Molecular Medicine · doi:10.3858/emm.2012.44.2.031 · Cited by 348
“The mutant α-synuclein is degraded by macroautophagy instead of CMA.”
BackgroundInfluentialLysosomal Degradation of α-Synuclein in Vivo
Mak, S. K., McCormack, A. L., Manning-Boğ, A. B., Cuervo, A. M., & Di Monte, D. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.074617 · Cited by 349
Lipid droplets: a classic organelle with new outfits
Fujimoto, T., Ohsaki, Y., Cheng, J., Suzuki, M., & Shinohara, Y. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0449-0 · Cited by 343
“Interestingly, -synuclein, a major protein of Lewy bodies found in the Parkinson’s disease as well as other synucleinopathies, also has an aYnity to the LD (Cole et al. 2002) and is degraded both by the proteasome and autophagy (Webb et al. 2003).”
BackgroundAutophagy in Huntington disease and huntingtin in autophagy
Martin, D. D. O., Ladha, S., Ehrnhoefer, D. E., & Hayden, M. R. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2014.09.003 · Cited by 350
Oueslati, A., Fournier, M., & Lashuel, H. A. (2010) · Progress in Brain Research · doi:10.1016/s0079-6123(10)83007-9 · Cited by 347
A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin
Sarkar, S., Krishna, G., Imarisio, S., Saiki, S., O'Kane, C. J., & Rubinsztein, D. C. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddm294 · Cited by 349
Self-citationTargeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
Fields, C. R., Bengoa-Vergniory, N., & Wade-Martins, R. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00299 · Cited by 328
Autophagy and the ubiquitin-proteasome system: Collaborators in neuroprotection
Nedelsky, N. B., Todd, P. K., & Taylor, J. P. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.002 · Cited by 351
“The neuronal protein α-synuclein, for example, can be degraded by the UPS, macroautophagy and chaperone-mediated autophagy [26,29].”
BackgroundInfluentialStimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy
Schaeffer, V., Lavenir, I., Ozcelik, S., Tolnay, M., Winkler, D. T., & Goedert, M. (2012) · Brain · doi:10.1093/brain/aws143 · Cited by 343
Lysosomal impairment in Parkinson's disease
Dehay, B., Martinez‐Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson, M. R., Klein, C., Vila, M., & Bezard, E. (2013) · Movement Disorders · doi:10.1002/mds.25462 · Cited by 340
Role of mTOR in physiology and pathology of the nervous system
Swiech, L., Perycz, M., Malik, A., & Jaworski, J. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.08.015 · Cited by 338
“The aggregation of these proteins is linked to the spinocerebral ataxia, AD and PD, respectively [21,142,143].”
BackgroundOsellame, L. D., Rahim, A. A., Hargreaves, I. P., Gegg, M. E., Richard-Londt, A., Brandner, S., Waddington, S. N., Schapira, A. H. V., & Duchen, M. R. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.014 · Cited by 334
“The lysosomal degradation pathway is primarily responsible for the clearance of a-synuclein intermediate species, although there is mounting evidence for a role of the proteasome (Webb et al., 2003).”
BackgroundKhandia, R., Dadar, M., Munjal, A., Dhama, K., Karthik, K., Tiwari, R., Yatoo, M. I., Iqbal, H. M. N., Singh, K. P., Joshi, S. K., et al. (2019) · Cells · doi:10.3390/cells8070674 · Cited by 314
“Autophagy is involved in the cytoplasmic clearance of α-synuclein (α-syn), which is observed in Parkinson’s disease [336].”
BackgroundMicroglia Phenotypes in Aging and Neurodegenerative Diseases
Wendimu, M. Y., & Hooks, S. B. (2022) · Cells · doi:10.3390/cells11132091 · Cited by 336
Hebron, M. L., Lonskaya, I., & Moussa, C. E. H. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt192 · Cited by 325
Autophagy and neurodegeneration
Frake, R. A., Ricketts, T., Menzies, F. M., & Rubinsztein, D. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73944 · Cited by 332
“In vitro work examining the effect of autophagy upregulation on the clearance of a wide range of aggregation-prone proteins including those with polyQ and polyA expansions (5, 8), mutant tau and ataxin-3 (8), and mutant α-synuclein (6, 94) has suggested reductions in Downloaded from http://www.”
BackgroundSelf-citationLewy Body-like α-Synuclein Aggregates Resist Degradation and Impair Macroautophagy
Tanik, S. A., Schultheiss, C. E., Volpicelli-Daley, L. A., Brunden, K. R., & Lee, V. M. Y. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.457408 · Cited by 326
Autophagy in neurodegenerative disease: friend, foe or turncoat?
Nixon, R. A. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.07.003 · Cited by 314
Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection
Renna, M., Schaffner, C., Brown, K., Shang, S., Tamayo, M. H., Hegyi, K., Grimsey, N. J., Cusens, D., Coulter, S., Cooper, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46095 · Cited by 314
“7, 16), we examined the clearance of 2 known autophagy substrates: mutant (Q74) huntingtin (17) and A53T α-syncuclein (18).”
BackgroundSelf-citationChaperone-mediated autophagy in aging and disease
Massey, A. C., Zhang, C., & Cuervo, A. M. (2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(05)73007-6 · Cited by 315
HDAC inhibitor‐based therapies: Can we interpret the code?
New, M., Olzscha, H., & La Thangue, N. B. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 310
“It is hypothesized that autophagy is a salvage pathway to complement the UPS when it is overwhelmed or impaired by undegradable substrates, such as aggregating proteins (Webb et al., 2003).”
BackgroundEmerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
Extracellular α-synuclein—a novel and crucial factor in Lewy body diseases
Lee, H.-J., Bae, E.-J., & Lee, S.-J. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.275 · Cited by 306
Regulation of Neuronal Survival Factor MEF2D by Chaperone-Mediated Autophagy
Yang, Q., She, H., Gearing, M., Colla, E., Lee, M., Shacka, J. J., & Mao, Z. (2009) · Science · doi:10.1126/science.1166088 · Cited by 304
Cullen, V., Sardi, S. P., Ng, J., Xu, Y., Sun, Y., Tomlinson, J. J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22400 · Cited by 303
“The Mutant GBA Effect on a-Synuclein Can Be Reversed Pharmacologically in Cells To determine whether the mtGBA effect on SNCA described above could be ameliorated pharmacologically, we extended our cell-based drug screening efforts in PC12-SNCA cells (eg, Supplementary Fig 2)(18) and treated cells with the macroautoph…”
BackgroundAlpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship
Xilouri, M., Brekk, O. R., & Stefanis, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8341-2 · Cited by 299
“The Rubinsztein lab found that alpha-synuclein was indeed located within lysosomal compartments of cultured neuronal cells and that the degradation of PD-linked mutant, but not of wild-type alpha-synuclein was attenuated by application of macroautophagy inhibitors [62].”
Ravikumar, B., Imarisio, S., Sarkar, S., O'Kane, C. J., & Rubinsztein, D. C. (2008) · Journal of Cell Science · doi:10.1242/jcs.025726 · Cited by 301
“…this pathway appears to be equally important for the clearance of several other intracellular proteins that cause neurodegeneration, including the A53T point mutation in α-synuclein that causes autosomal-dominant Parkinson disease (Berger et al., 2006; Ravikumar et al., 2002; Webb et al., 2003).”
Self-citationSevlever, D., Jiang, P., & Yen, S.-H. C. (2008) · Biochemistry · doi:10.1021/bi800699v · Cited by 305
Differential Interactions Between Beclin 1 and Bcl-2 Family Members
Erlich, S., Mizrachy, L., Segev, O., Lindenboim, L., Zmira, O., Adi-Harel, S., Hirsch, J. A., Stein, R., & Pinkas-Kramarski, R. (2007) · Autophagy · doi:10.4161/auto.4713 · Cited by 292
Friedman, L. G., Lachenmayer, M. L., Wang, J., He, L., Poulose, S. M., Komatsu, M., Holstein, G. R., & Yue, Z. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5809-11.2012 · Cited by 303
“Since multiple studies have linked autophagy to the clearance of α-syn (Webb et al., 2003; Rideout et al., 2004), we asked whether TH+ neurons of cKOTH mice develop aberrant αsyn levels.”
BackgroundInfluentialFocal cerebral ischemia induces upregulation of Beclin 1 and autophagy-like cell death
Rami, A., Langhagen, A., & Steiger, S. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.08.005 · Cited by 296
“In contrast, other studies indicate a neuroprotective role for autophagy in Huntington’s disease and á-synucleopathies (Webb et al., 2003).”
ResultDeficiency of ATP13A2 Leads to Lysosomal Dysfunction, α-Synuclein Accumulation, and Neurotoxicity
Usenovic, M., Tresse, E., Mazzulli, J. R., Taylor, J. P., & Krainc, D. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5575-11.2012 · Cited by 291
“While clearance of normal -syn is likely mediated by the ubiquitin-proteasome system (Webb et al., 2003), recent evidence suggests that autophagy-lysosomal pathway mediates clearance of accumulated and aggregated -syn (Cuervo et al., 2004; Mazzulli et al., 2011).”
BackgroundCell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0309-3 · Cited by 287
“Mutant forms of a-Syn inhibit CMA [80].”
InfluentialEnhanced autophagy ameliorates cardiac proteinopathy
Bhuiyan, M. S., Pattison, J. S., Osinska, H., James, J., Gulick, J., McLendon, P. M., Hill, J. A., Sadoshima, J., & Robbins, J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70877 · Cited by 298
Autophagy and disease: always two sides to a problem
Sridhar, S., Botbol, Y., Macian, F., & Cuervo, A. M. (2012) · The Journal of Pathology · doi:10.1002/path.3025 · Cited by 293
Functional Consequences of α-Synuclein Tyrosine Nitration
Hodara, R., Norris, E. H., Giasson, B. I., Mishizen-Eberz, A. J., Lynch, D. R., Lee, V. M.-Y., & Ischiropoulos, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408906200 · Cited by 286
Rapamycin is a neuroprotective treatment for traumatic brain injury
Erlich, S., Alexandrovich, A., Shohami, E., & Pinkas-Kramarski, R. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.003 · Cited by 295
“It was also demonstrated that induction of autophagy by rapamycin enhances the clearance of a wide range of aggregate-prone proteins and reduces their toxicity (Berger et al., 2006; Webb et al., 2003).”
BackgroundSimonsen, A., Birkeland, H. C. G., Gillooly, D. J., Mizushima, N., Kuma, A., Yoshimori, T., Slagsvold, T., Brech, A., & Stenmark, H. (2004) · Journal of Cell Science · doi:10.1242/jcs.01287 · Cited by 281
“Degradation of cytoplasmic proteins can occur by proteasomal proteolysis or by autophagy (Webb et al., 2003).”
BackgroundTherapeutic potential of autophagy-enhancing agents in Parkinson’s disease
Moors, T. E., Hoozemans, J. J. M., Ingrassia, A., Beccari, T., Parnetti, L., Chartier-Harlin, M.-C., & van de Berg, W. D. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0154-3 · Cited by 278
“Rapamycin was able to reduce α-syn accumulation and blocked α-syn induced neurodegeneration in wild-type, A30P, or A53T α-syn expressing PC12 cells [4] and in α-syn-overexpressing mice [68] and rats [70], respectively.”
BackgroundInfluentialCathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo
Cullen, V., Lindfors, M., Ng, J., Paetau, A., Swinton, E., Kolodziej, P., Boston, H., Saftig, P., Woulfe, J., Feany, M. B., et al. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-5 · Cited by 279
“However, growing evidence has indicated that the lysosome, as well as the proteasome, can mediate degradation of aSyn [22,23].”
Autophagy and Alpha‐Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies
Xilouri, M., Brekk, O. R., & Stefanis, L. (2016) · Movement Disorders · doi:10.1002/mds.26477 · Cited by 261
Mechanisms and Functions of Spatial Protein Quality Control
Sontag, E. M., Samant, R. S., & Frydman, J. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014616 · Cited by 274
“Consistent with this hypothesis, several aggregation-prone proteins can be degraded by either pathway (33, 159, 160).”
BackgroundNeurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease
Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., Dardis, A., Deganuto, M., De Carlo, C., Castrioto, A., et al. (2014) · Movement Disorders · doi:10.1002/mds.25772 · Cited by 266
“Both T369M and E326K have been reported as single alterations in patients affected by PD.28,33-35 In a postmortem investigation carried out in brains from PD patients, either with heterozygous GBA mutations or with sporadic disease, GCase activity was significantly decreased in several brain areas of both groups, heav…”
BackgroundInfluentialAutophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain
Keller, J. N., Dimayuga, E., Chen, Q., Thorpe, J., Gee, J., & Ding, Q. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.05.003 · Cited by 271
Ubiquitin ligase Nedd4 promotes α-synuclein degradation by the endosomal–lysosomal pathway
Tofaris, G. K., Kim, H. T., Hourez, R., Jung, J.-W., Kim, K. P., & Goldberg, A. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109356108 · Cited by 271
“(1-120): Implications for Lewy body disorders.”
BackgroundMutant A53T α-Synuclein Induces Neuronal Death by Increasing Mitochondrial Autophagy
Choubey, V., Safiulina, D., Vaarmann, A., Cagalinec, M., Wareski, P., Kuum, M., Zharkovsky, A., & Kaasik, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.132514 · Cited by 262
Protein damage, repair and proteolysis
Chondrogianni, N., Petropoulos, I., Grimm, S., Georgila, K., Catalgol, B., Friguet, B., Grune, T., & Gonos, E. S. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.09.001 · Cited by 256
Tang, F.-L., Erion, J. R., Tian, Y., Liu, W., Yin, D.-M., Ye, J., Tang, B., Mei, L., & Xiong, W.-C. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0042-15.2015 · Cited by 269
“WT -synuclein is degraded by both pathways: CMA and ubiquitin-proteasomal (Webb et al., 2003).”
BackgroundA Precipitating Role for Truncated α-Synuclein and the Proteasome in α-Synuclein Aggregation
Liu, C.-W., Giasson, B. I., Lewis, K. A., Lee, V. M., DeMartino, G. N., & Thomas, P. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501508200 · Cited by 269
Pickford, F., Masliah, E., Britschgi, M., Lucin, K., Narasimhan, R., Jaeger, P. A., Small, S., Spencer, B., Rockenstein, E., Levine, B., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33585 · Cited by 268
Tsvetkov, A. S., Miller, J., Arrasate, M., Wong, J. S., Pleiss, M. A., & Finkbeiner, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004498107 · Cited by 266
“Statistical analysis used Metamorph (Molecular Devices, CA), as described (2, 4), with cumulative hazard curves generated by Statview (Apple, CA).”
BackgroundMethodNilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265
“Evidence suggests that autophagy is impaired in neurodegenerative disorders, including PD [1–8]; leading to accumulation and propagation of misfolded -synuclein and SN neuronal degeneration.”
BackgroundLysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity
Qiao, L., Hamamichi, S., Caldwell, K. A., Caldwell, G. A., Yacoubian, T. A., Wilson, S., Xie, Z.-L., Speake, L. D., Parks, R., Crabtree, D., et al. (2008) · Molecular Brain · doi:10.1186/1756-6606-1-17 · Cited by 263
“Experiments in vitro have shown that α-syn can be cleared by the cytosolic ubiquitin-proteasome system (UPS), and/ or lysosome-mediated autophagic pathways[2].”
BackgroundAnionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation
Liu, Z., Sokratian, A., Duda, A. M., Xu, E., Stanhope, C., Fu, A., Strader, S., Li, H., Yuan, Y., Bobay, B. G., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi8716 · Cited by 262
“…the principle degradative organelle in neurons that metabolizes both endogenous low-molecular-weight α-synuclein and α-synuclein aggregates ( 39 – 42 ), we created a BODIPY-labeled dye-quenched α-synuclein fibril tool [i.e., DQ-α-synuclein] to measure the degradation of α-synuclein at the…”
MethodTherapeutic Targeting of Autophagy in Disease: Biology and Pharmacology
Cheng, Y., Ren, X., Hait, W. N., & Yang, J.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007120 · Cited by 262
Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease
Gan-Or, Z., Dion, P. A., & Rouleau, G. A. (2015) · Autophagy · doi:10.1080/15548627.2015.1067364 · Cited by 260
Protein degradation pathways in Parkinson’s disease: curse or blessing
Ebrahimi-Fakhari, D., Wahlster, L., & McLean, P. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1004-6 · Cited by 253
“Mutant A53T and A30P a-synuclein are degraded by both the UPS [10, 160, 171, 173] and macroautophagy [129, 132, 160, 173, 175], although this was questioned in other studies [3, 82].”
BackgroundResultAgeing and neurodegenerative diseases
Hung, C.-W., Chen, Y.-C., Hsieh, W.-L., Chiou, S.-H., & Kao, C.-L. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.08.006 · Cited by 247
Oxidative Stress and Autophagy in Cardiac Disease, Neurological Disorders, Aging and Cancer
Essick, E. E., & Sam, F. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.3.12106 · Cited by 249
Autophagy in Spinal Cord Motor Neurons in Sporadic Amyotrophic Lateral Sclerosis
Sasaki, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182160690 · Cited by 249
Thayanidhi, N., Helm, J. R., Nycz, D. C., Bentley, M., Liang, Y., & Hay, J. C. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-09-0801 · Cited by 229
“mental Figure S2, A and B) (Webb et al., 2003), consistent”
BackgroundXu, L., & Pu, J. (2016) · Parkinson's Disease · doi:10.1155/2016/1720621 · Cited by 230
Autophagy Induction as a Therapeutic Strategy for Neurodegenerative Diseases
Djajadikerta, A., Keshri, S., Pavel, M., Prestil, R., Ryan, L., & Rubinsztein, D. C. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.12.035 · Cited by 236
“[4] Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC.”
BackgroundSelf-citationPathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease
Overk, C. R., & Masliah, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.015 · Cited by 242
Ejlerskov, P., Rasmussen, I., Nielsen, T. T., Bergström, A.-L., Tohyama, Y., Jensen, P. H., & Vilhardt, F. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.401174 · Cited by 236
Autophagy: molecular mechanisms, physiological functions and relevance in human pathology
Mariño, G., & López-Otín, C. (2004) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-004-4012-4 · Cited by 239
“Accordingly, autophagy induction can reduce the formation of insoluble polyglutamine inclusion bodies under certain cell culture conditions [107] .”
BackgroundAggregate‐Prone Proteins Are Cleared from the Cytosol by Autophagy: Therapeutic Implications
Williams, A., Jahreiss, L., Sarkar, S., Saiki, S., Menzies, F. M., Ravikumar, B., & Rubinsztein, D. C. (2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)76003-3 · Cited by 239
“Our data with ‐synuclein mutants suggest that autophagy does eVectively remove soluble species, as these proteins do not form aggregates in our cell lines (Webb et al., 2003).”
BackgroundSelf-citationAutophagy is an adaptive response in desmin-related cardiomyopathy
Tannous, P., Zhu, H., Johnstone, J. L., Shelton, J. M., Rajasekaran, N. S., Benjamin, I. J., Nguyen, L., Gerard, R. D., Levine, B., Rothermel, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706802105 · Cited by 233
Cysteine cathepsins are essential in lysosomal degradation of α-synuclein
McGlinchey, R. P., & Lee, J. C. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500937112 · Cited by 231
Cell-produced α-synuclein oligomers are targeted to, and impair, the 26S proteasome
Emmanouilidou, E., Stefanis, L., & Vekrellis, K. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.07.008 · Cited by 221
Cdk5: a multifaceted kinase in neurodegenerative diseases
Cheung, Z. H., & Ip, N. Y. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.11.003 · Cited by 233
Emerging Roles for Lipid Droplets in Immunity and Host-Pathogen Interactions
Saka, H. A., & Valdivia, R. (2012) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-153958 · Cited by 220
“Similarly, the Parkinson’s disease protein α-synuclein, which is degraded both through autophagy and the proteasome, also accumulates on the surface of LDs in lipid-loading conditions (Cole et al. 2002, Webb et al. 2003).”
BackgroundChiu, C.-T., & Chuang, D.-M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.006 · Cited by 229
Mitophagy and Parkinson's disease: The PINK1–parkin link
Deas, E., Wood, N. W., & Plun-Favreau, H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.08.007 · Cited by 222
Autophagy and mitophagy in cellular damage control
Zhang, J. (2013) · Redox Biology · doi:10.1016/j.redox.2012.11.008 · Cited by 220
“Both chaperone-mediated autophagy and macroautophagy have been shown to participate in a-synuclein degradation, along with proteasomes [9] (Fig.”
BackgroundKabuta, T., Furuta, A., Aoki, S., Furuta, K., & Wada, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801918200 · Cited by 227
Bellucci, A., Navarria, L., Zaltieri, M., Falarti, E., Bodei, S., Sigala, S., Battistin, L., Spillantini, M., Missale, C., & Spano, P. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07143.x · Cited by 225
Increased autophagy in transgenic mice with a G93A mutant SOD1 gene
Morimoto, N., Nagai, M., Ohta, Y., Miyazaki, K., Kurata, T., Morimoto, M., Murakami, T., Takehisa, Y., Ikeda, Y., Kamiya, T., et al. (2007) · Brain Research · doi:10.1016/j.brainres.2007.06.045 · Cited by 223
Firefly luciferase mutants as sensors of proteome stress
Gupta, R., Kasturi, P., Bracher, A., Loew, C., Zheng, M., Villella, A., Garza, D., Hartl, F. U., & Raychaudhuri, S. (2011) · Nature Methods · doi:10.1038/nmeth.1697 · Cited by 219
Kabuta, T., Suzuki, Y., & Wada, K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603337200 · Cited by 219
Jiang, T.-F., Zhang, Y.-J., Zhou, H.-Y., Wang, H.-M., Tian, L.-P., Liu, J., Ding, J.-Q., & Chen, S.-D. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9431-7 · Cited by 220
“Current investigations represented that autophagy instead of UPS is the main pathway for A53T a-syn clearance (Webb et al. 2003; Lan et al. 2012).”
Mechanisms of selective autophagy and mitophagy: Implications for neurodegenerative diseases
Chu, C. T. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.07.015 · Cited by 218
The immunology of neurodegeneration
Czirr, E., & Wyss-Coray, T. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58656 · Cited by 213
“Defects in autophagy, as they occur in neurodegenerative diseases (13–16), might thus interfere with such an innate immune process.”
Autophagy in Neurodegenerative Diseases: A Hunter for Aggregates
Park, H., Kang, J.-H., & Lee, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093369 · Cited by 207
Renna, M., Jimenez-Sanchez, M., Sarkar, S., & Rubinsztein, D. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.072181 · Cited by 208
Self-citationParkinson’s disease as a result of aging
Rodriguez, M., Rodriguez‐Sabate, C., Morales, I., Sanchez, A., & Sabate, M. (2015) · Aging Cell · doi:10.1111/acel.12312 · Cited by 214
“This is not the case of SN cells Correspondence”
BackgroundBoosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration
Xilouri, M., Brekk, O. R., Landeck, N., Pitychoutis, P. M., Papasilekas, T., Papadopoulou-Daifoti, Z., Kirik, D., & Stefanis, L. (2013) · Brain · doi:10.1093/brain/awt131 · Cited by 205
“Besides CMA, macroautophagy was also found to be responsible for the degradation of a-synuclein in various systems (Webb et al., 2003; Lee et al., 2004; Vogiatzi et al., 2008), and there is extensive literature suggesting that the augmentation of macro- autophagy may be beneficial in…”
Background
Metadata
- Authors
- Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C.
- Affiliations
- Addenbrooke's Hospital (GB)
- University of Cambridge (GB)
- Corresponding author
- Rubinsztein, David C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-07
- Volume
- 278
- Issue
- 27
- Pages
- 25009-25013
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2157535220
- Cited by
- 1,429
- References
- 37
- Citations by year
- 2026: 36 · 2025: 41 · 2024: 76 · 2023: 50 · 2022: 68 · 2021: 71 · 2020: 83 · 2019: 85 · 2018: 77 · 2017: 62 · 2016: 65 · 2015: 65 · 2014: 75 · 2013: 79 · 2012: 95
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6305 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Parkinson's UK
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- alpha-synuclein, Parkinson's disease, autophagy, proteasome, protein degradation, Lewy bodies, A30P mutation, A53T mutation, PC12 cells, rapamycin, autophagic vesicles, dopaminergic neurons
- MeSH terms
- Animals, Antibiotics, Antineoplastic, Autophagy, Cysteine Endopeptidases, Humans, Multienzyme Complexes, Nerve Tissue Proteins, PC12 Cells, Sirolimus, Proteasome Endopeptidase Complex, Rats, Synucleins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.